IL86423A0 - Pharmaceutical compositions for the treatment of alzheimer's disease - Google Patents

Pharmaceutical compositions for the treatment of alzheimer's disease

Info

Publication number
IL86423A0
IL86423A0 IL86423A IL8642388A IL86423A0 IL 86423 A0 IL86423 A0 IL 86423A0 IL 86423 A IL86423 A IL 86423A IL 8642388 A IL8642388 A IL 8642388A IL 86423 A0 IL86423 A0 IL 86423A0
Authority
IL
Israel
Prior art keywords
alzheimer
disease
treatment
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
IL86423A
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL86423A0 publication Critical patent/IL86423A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
IL86423A 1987-05-19 1988-05-18 Pharmaceutical compositions for the treatment of alzheimer's disease IL86423A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5189787A 1987-05-19 1987-05-19
US18800588A 1988-05-11 1988-05-11

Publications (1)

Publication Number Publication Date
IL86423A0 true IL86423A0 (en) 1988-11-15

Family

ID=26729929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86423A IL86423A0 (en) 1987-05-19 1988-05-18 Pharmaceutical compositions for the treatment of alzheimer's disease

Country Status (3)

Country Link
AU (1) AU1790988A (en)
IL (1) IL86423A0 (en)
WO (1) WO1988009171A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5760021A (en) * 1992-05-29 1998-06-02 The Procter & Gamble Company Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
ATE311864T1 (en) * 1993-03-29 2005-12-15 PROPANE-1,3-DISULPHONIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF AMYLOIDOSIS
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6008188A (en) * 1994-05-06 1999-12-28 Kanebo Limited Cytokine potentiator and pharmaceutical formulation for cytokine administration
EP1004301A4 (en) * 1997-07-28 2002-11-13 Riken Protecting and survival promoting agent for central nervous cell
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
IL131334A0 (en) * 1999-08-10 2001-01-28 Yeda Res & Dev Pharmaceutical compositions comprising hydroxyamines
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
WO2007125385A2 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
CN114099487A (en) * 2021-12-22 2022-03-01 上海市第一人民医院 Application of ethanolamine in preparation of product for preventing, relieving and/or treating neuroinflammation related diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437834A1 (en) * 1978-10-04 1980-04-30 Lejeune Jerome L-serine or glycine for treatment of cerebral deficiencies - such as mongolism and general mental debility, etc.
US4569929A (en) * 1980-02-29 1986-02-11 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation

Also Published As

Publication number Publication date
AU1790988A (en) 1988-12-21
WO1988009171A1 (en) 1988-12-01

Similar Documents

Publication Publication Date Title
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
ZA829335B (en) Pharmaceutical preparation for treating alzheimer's disease
EP0541686A4 (en) Tachykinin agonists for treatment of alzheimer's disease
EP0243002A3 (en) Pharmaceutical composition for the treatment of periodontal diseases
GB2188844B (en) Pharmaceutical composition for the treatment of psoriasis
EP0331620A3 (en) Agent for the treatment of parkinson's disease
IL76561A (en) Pharmaceutical compositions containing ifn-ypsilon for the treatment of rheumatic diseases
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
IL104132A0 (en) Compositions for the treatment of mammalian diseases
EP0297296A3 (en) Process for the preparation of 2,2'-oxybisûn,n-dimethyl-ethylamine¨
IL93242A0 (en) Pharmaceutical preparation for the treatment of tonsillitis
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
CS22891A2 (en) Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases
IL96455A0 (en) Pharmaceutical compositions for the treatment of hsv
IL94402A0 (en) Pharmaceutical compositions containing imidazodiazepines for the treatment of neurological symptoms
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
ZA915462B (en) Composition for the treatment of alzheimer's disease and process for preparing the same
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
GB8728036D0 (en) Therapy for alzheimer's disease
IL89431A0 (en) Pharmaceutical compositions for the treatment of autoimmune diseases
GB8709861D0 (en) Pharmaceutical compositions & treatment
GB8709862D0 (en) Pharmaceutical compositions & treatment
GB8709860D0 (en) Pharmaceutical compositions & treatment